Oppenheimer & Co
ZNTL icon

Oppenheimer & Co’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Oppenheimer & Co’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$36K Buy
13,000
+344
+3% +$1.39K ﹤0.01% 1736
2026
Q2 		$61.4K Buy
+12,656
New +$50.5K ﹤0.01% 1734

Other funds holding ZNTL

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Patient Square Capital
Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

Oppenheimer & Co's ZNTL Position: Q3 2026 in Review

Oppenheimer & Co increased its Zentalis Pharmaceuticals (ZNTL) stake by 2.7% in Q3 2026, buying an estimated $1.39K and bringing the position to 13,000 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #1736.

Oppenheimer & Co first reported a position in ZNTL in Q2 2026 and has held it in 2 quarters since. The position peaked at $61.4K in Q2 2026. 45 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.

  • Oppenheimer & Co held 13,000 shares of Zentalis Pharmaceuticals worth $36K as of Q3 2026.
  • Oppenheimer & Co bought 344 Zentalis Pharmaceuticals shares in Q3 2026, an estimated $1.39K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1736 holding.
  • Oppenheimer & Co first reported a position in Zentalis Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Oppenheimer & Co's Zentalis Pharmaceuticals position peaked at $61.4K in Q2 2026.
  • 45 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.